|
|
|
Volumn 122, Issue 27, 2002, Pages 2619-2623
|
|
Applications to add new drugs to the Norwegian drug reimbursement program;Vurderinger av refusjonssøknader for nye legemidler
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACICLOVIR;
ALBYL E;
ANGIOTENSIN ANTAGONIST;
ANTIASTHMATIC AGENT;
BECLOMETASONE DIPROPIONATE;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
BLOOD CLOTTING FACTOR;
CALCIUM ANTAGONIST;
CAPTOPRIL;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
ESTRADIOL PLUS NORETHISTERONE ACETATE;
ESTRIOL;
ETANERCEPT;
FENOTEROL;
FLUTICASONE PROPIONATE PLUS SALMETEROL;
FLUVOXAMINE MALEATE;
GLUCOCORTICOID;
HUMAN GROWTH HORMONE;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
IMMUNOSUPPRESSIVE AGENT;
INTERFERON BETA SERINE;
LEUKOTRIENE RECEPTOR BLOCKING AGENT;
LOSARTAN POTASSIUM;
MEVINOLIN;
MONTELUKAST;
NAFARELIN ACETATE;
NICOTINE;
NICOTINE GUM;
NIFEDIPINE;
OMEGA 3 FATTY ACID;
OMEPRAZOLE;
ONDANSETRON;
PACLITAXEL;
PROTON PUMP INHIBITOR;
RECOMBINANT BLOOD CLOTTING FACTOR 8;
RECOMBINANT ERYTHROPOIETIN;
RECOMBINANT FOLLITROPIN;
SEROTONIN UPTAKE INHIBITOR;
SILDENAFIL;
SUMATRIPTAN;
SUMATRIPTAN SUCCINATE;
TERBUTALINE;
TETRAHYDROLIPSTATIN;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
ARTICLE;
COST EFFECTIVENESS ANALYSIS;
DECISION MAKING;
DRUG COST;
DRUG EFFICACY;
DRUG INDUCED DISEASE;
DRUG INFORMATION;
DRUG RESEARCH;
EVALUATION;
INFORMATION PROCESSING;
REIMBURSEMENT;
RISK ASSESSMENT;
RISK FACTOR;
COST-BENEFIT ANALYSIS;
DECISION MAKING;
DRUG COSTS;
DRUGS, INVESTIGATIONAL;
FORMULARIES;
HUMANS;
INSURANCE, PHARMACEUTICAL SERVICES;
NORWAY;
REIMBURSEMENT MECHANISMS;
|
|
EID: 0037058386
PISSN: 00292001
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (7)
|
|
References (7)
|
